Drugs to Prevent and Treat Malaria Advanced Tech
Abstract
This Project covers technology development, demonstration, and transition of a candidate malaria prevention drug with weekly or less frequent dosing. The candidate drug may also be effective for the treatment of P. falciparum and P. vivax malaria. Infectious disease prevention sustains individual and unit readiness and reduces health services requirements and cost. Research is conducted in compliance with Food and Drug Administration (FDA) regulations for medical products for human use. Work is managed by the United States (U.S.) Army Medical Research and Development Command (USAMRDC) in coordination with the Naval Medical Research Center (NMRC). The Army is responsible for programming and funding all Department of Defense (DoD) naturally occurring infectious disease research requirements, thereby precluding duplication of effort within the Military Departments. Promising medical countermeasures identified in this Project are further matured under PE 0603807A (Medical Systems Advanced Development), Project 808 (DoD Drug & Vacc Ad). The cited work is consistent with the Under Secretary of Defense (Research and Engineering) science and technology focus areas and the Army Modernization Strategy. All FY20 adjustments align program resources to Army Modernization Priorities in support of the National Defense Strategy. Work in this Project is performed by: the United States Army Medical Research and Development Command (USAMRDC), Fort Detrick, MD. Efforts in this Project support the Soldier portfolio and the principal area of Military Relevant Infectious Diseases.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2021
- Source ID
- MN8_0603002A_3_2040_PB_2021
Related Documents
- Root: Medical Advanced Technology
- Child Accomplishment: Drugs to Prevent and Treat Malaria Advanced Technology
- Child Accomplishment: FY 2020 SBIR/STTR Transfer